Iridium-192 brachytherapy in combination with interstitial microwave-induced hyperthermia for malignant glioma.
A phase I clinical trial assessing the feasibility and safety of hyperthermia in combination with 192Ir brachytherapy (60 Gy) for the treatment of malignant glioma now includes 14 patients. Hyperthermia (42-43 degrees C at tumor margin for 60 min) has been induced using stereotactically implanted afterloading catheters and a microwave (915 or 2,450 MHz) antenna array. Thermometry recorded along each catheter confirms the general ability of the technique to heat such volumes, but thermal heterogeneities are documented. Transient or permanent worsening of previous neurologic deficit, seen in 7 patients, has been the most common morbidity.
Roberts
D W
DW
Dartmouth-Hitchcock Medical Center, Dartmouth College, Hanover, N.H.
Strohbehn
J W
JW
Coughlin
C T
CT
Ryan
T P
TP
Lyons
B E
BE
Douple
E B
EB
D000328:Adult; D000368:Aged; D001918:Brachytherapy; D001932:Brain Neoplasms / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D005910:Glioma / Q000532:radiotherapy*; D006801:Humans; D006979:Hyperthermia, Induced; D007496:Iridium Radioisotopes / Q000627:therapeutic use*; D008872:Microwaves / Q000627:therapeutic use*; D008875:Middle Aged; D013238:Stereotaxic Techniques
D007496:Iridium Radioisotopes